{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T19:45:36Z","timestamp":1789933536831,"version":"4.0.1"},"reference-count":12,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2011,5,31]],"date-time":"2011-05-31T00:00:00Z","timestamp":1306800000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1002\/ajh.22051","type":"journal-article","created":{"date-parts":[[2011,4,18]],"date-time":"2011-04-18T13:42:26Z","timestamp":1303134146000},"page":"610-611","source":"Crossref","is-referenced-by-count":75,"title":["Nilotinib treatment\u2010associated peripheral artery disease and sudden death: Yet another reason to stick to imatinib as front\u2010line therapy for chronic myelogenous leukemia"],"prefix":"10.1002","volume":"86","author":[{"given":"Ayalew","family":"Tefferi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Letendre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,5,31]]},"reference":[{"key":"e_1_2_1_5_1_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.22037"},{"key":"e_1_2_1_5_1_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"e_1_2_1_5_1_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315"},{"key":"e_1_2_1_5_1_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25600"},{"key":"e_1_2_1_5_1_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.0779"},{"key":"e_1_2_1_5_1_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.8154"},{"key":"e_1_2_1_5_1_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_2_1_5_1_9_2","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2010.32.0598","article-title":"Tolerability\u2010adapted imatinib 800 mg\/d versus 400 mg\/d versus 400 mg\/d plus interferon\u2010{alpha} in newly diagnosed chronic myeloid leukemia","author":"Hehlmann R","year":"2011","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_5_1_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1004095"},{"key":"e_1_2_1_5_1_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.38"},{"key":"e_1_2_1_5_1_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-277152"},{"key":"e_1_2_1_5_1_13_2","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djr060","article-title":"Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib","author":"Gambacorti\u2010Passerini C","year":"2011","journal-title":"J Natl Cancer Inst"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.22051","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.22051","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T16:28:44Z","timestamp":1700584124000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.22051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,31]]},"references-count":12,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["10.1002\/ajh.22051"],"URL":"https:\/\/doi.org\/10.1002\/ajh.22051","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,31]]}}}